PRESERVE-006: ONC-392 plus Pluvicto in ARTA resistant mCRPC - Clinical Trial
Who Can Participate in the Study?
Grupo etario
Adultos
Study Details
Full Title
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
Principal Investigator
Especialista en oncología médica
Protocol Number
IRB:
PRO00113824
NCT:
NCT05682443
Phase
Phase
II
ClinicalTrials.gov
View on ClinicalTrials.gov
Estado de inscripción
Abierto para inscripción